Pradip Nair
Bengaluru, KA, India
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Deciphering T-cell exhaustion in the tumor microenvironment: paving the way for innovative solid tumor therapies.
Journal: Frontiers in immunology
Published: December 19, 2024
BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth.
Journal: Cancer research
Published: December 27, 2021
Analytical similarity assessment of MYL-1402O to reference Bevacizumab.
Journal: Expert opinion on biological therapy
Published: September 01, 2021
Predicting the Severity of Disease Progression in COVID-19 at the Individual and Population Level: A Mathematical Model.
Journal: Clinical & experimental pharmacology
Published: August 09, 2021
Predicting the severity of disease progression in COVID-19 at the individual and population level: A mathematical model.
Journal: medRxiv : the preprint server for health sciences
Published: April 14, 2021
T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab.
Journal: PloS one
Published: October 19, 2016
Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications.
Journal: Journal of immunology research
Published: March 04, 2016
Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.
Journal: Journal of the American Academy of Dermatology
Published: November 08, 2013
EGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs.
Journal: Cancer medicine
Published: February 24, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026